Welcome to the NUPLAZID® (pimavanserin) website. This information is intended for US healthcare professionals only. If you are a healthcare professional, click Continue.
You are about to leave
You will be redirected to a product website with information on a potential treatment option.
Do you want to continue?
You are now leaving NUPLAZIDhcp.com
FDA issues clear statement reaffirming the positive benefit-risk profile of NUPLAZID® (pimavanserin) for patients with hallucinations and delusions related to Parkinson’s disease psychosis.
Read more at FDA.gov
Stay on site